Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.75 |
| ▸ | INSR | P06213 | 9/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180184 | 0.94 | ALK (0.80) | ALKINSRKCNH2 | |
| SCHEMBL1013963 | 0.93 | ALK (0.80) | ALKINSRKCNH2 | |
| SCHEMBL31521764 | 0.93 | ALK (0.80) | ALKINSRKCNH2 | |
| SCHEMBL30761514 | 0.90 | ALK (0.81) | ALKINSRKCNH2 | |
| SCHEMBL28630275 | 0.90 | ALK (0.81) | ALKINSRKCNH2 | |
| SCHEMBL25566011 | 0.89 | ALK (0.86) | ALKINSRKCNH2 | |
| SCHEMBL28619835 | 0.87 | ALK (0.77) | ALKINSRKCNH2 | |
| SCHEMBL25566470 | 0.87 | ALK (0.73) | ALKINSRKCNH2 | |
| SCHEMBL1013964 | 0.87 | ALK (0.69) | ALKINSRKCNH2 | |
| SCHEMBL17879562 | 0.87 | ALK (0.73) | ALKINSRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336643-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| EP-4362939-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023278325-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336643-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | ALK, JMJD7, ALKBH3 | ALK 1/4885INSR 903/4885KCNH2 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.